Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MEDTRONIC PLC

(MDT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Medtronic plc Announces FDA Clearance and Results of Artificial Intelligence Algorithms for Cardiac Monitoring

07/28/2021 | 08:00am EDT

Medtronic plc announced U.S. Food and Drug Administration (FDA) clearance for two AccuRhythm™ AI algorithms for use with the LINQ II™ insertable cardiac monitor (ICM). AccuRhythm AI applies artificial intelligence (AI) to heart rhythm event data collected by LINQ II, improving the accuracy of information physicians receive so they can better diagnose and treat abnormal heart rhythms. AccuRhythm AI validation data will be presented this week at Heart Rhythm 2021, the Heart Rhythm Society's annual Heart Rhythm meeting. The small, wireless LINQ II ICM is the world's most accurate ICM,1-4 and the new cloud-based AccuRhythm AI algorithms further enhance LINQ II ICM's delivery of accurate heart rhythm alerts. The algorithms address the two most common ICM false alerts – atrial fibrillation (AF), an irregular or rapid rhythm in the upper chambers of the heart; and asystole, a long pause between heartbeats.5-6 Medtronic developed the AccuRhythm AI platform and initial algorithms using its proprietary, diverse and debiased database of more than 1 million electrocardiogram heart rhythm episodes. AccuRhythm AI validation results to be presented at Heart Rhythm 2021 include: The AF algorithm reduced LINQ II ICM false AF alerts by 74.1% and preserved 99.3% of true AF alerts. The Pause algorithm reduced LINQ II false pause alerts by 97.4% and preserved 100% of true pause alerts. The AccuRhythm AI algorithms will be released on the CareLink™ Network later this year for use by all implanted LINQ II devices in the United States. In collaboration with leading clinicians, researchers, and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services of the quality that deliver clinical and economic value to healthcare consumers and providers around the world.


© S&P Capital IQ 2021
All news about MEDTRONIC PLC
09/14Medtronic to Seek Acquisitions
CI
09/14MEDTRONIC : Says US Patent Office Rejects Axonics' Challenge to Bladder Device P..
MT
09/13MEDTRONIC : U.S. Patent and Trademark Office Rejects Axonics' Challenge to Medtr..
PR
09/13MEDTRONIC : Collaboration with Mpirik to Address Disparities in Care Associated ..
PR
09/13Medtronic Collaboration with Mpirik to Address Disparities in Care Associated..
CI
09/10MEDTRONIC PLC : Regulation FD Disclosure (form 8-K)
AQ
09/09MEDTRONIC : 2021 Virtual Wells Fargo Healthcare Conference Presentation
PU
09/07MEDTRONIC : Executives to Speak at Upcoming Investor Conferences
AQ
09/07MEDTRONIC : Announces NAVABLATE Study Results Released in Late-Breaking Podium P..
PR
09/07Medtronic plc Announces NAVABLATE Study Results Released in Late-Breaking Pod..
CI
More news
Analyst Recommendations on MEDTRONIC PLC
More recommendations
Financials (USD)
Sales 2022 32 995 M - -
Net income 2022 5 704 M - -
Net Debt 2022 20 694 M - -
P/E ratio 2022 32,7x
Yield 2022 1,85%
Capitalization 175 B 175 B -
EV / Sales 2022 5,92x
EV / Sales 2023 5,55x
Nbr of Employees 90 000
Free-Float 99,7%
Chart MEDTRONIC PLC
Duration : Period :
Medtronic plc Technical Analysis Chart | MDT | IE00BTN1Y115 | MarketScreener
Technical analysis trends MEDTRONIC PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 29
Last Close Price 129,70 $
Average target price 145,92 $
Spread / Average Target 12,5%
EPS Revisions
Managers and Directors
Geoffrey Straub Martha Chairman & Chief Executive Officer
Karen L. Parkhill Chief Financial Officer & Executive Vice President
Laura Mauri Chief Clinical & Regulatory Officer, Senior VP
Richard E. Kuntz Chief Medical & Scientific Officer, Senior VP
Gregory L. Smith Executive VP-Global Operations & Supply Chain
Sector and Competitors
1st jan.Capi. (M$)
MEDTRONIC PLC10.72%174 552
ABBOTT LABORATORIES15.80%224 776
BECTON, DICKINSON AND COMPANY4.69%75 229
HOYA CORPORATION30.10%62 323
ALIGN TECHNOLOGY, INC.34.62%56 839
SARTORIUS STEDIM BIOTECH79.60%56 591